




OPEN ACCESS

# Comparison of two devices for automated oxygen control in preterm infants: a randomised crossover trial

Hylke H Salverda <sup>1</sup>, Sophie J E Cramer,<sup>1</sup> Ruben S G M Witlox,<sup>1</sup> Timothy J Gale,<sup>2</sup> Peter A Dargaville,<sup>3,4</sup> Steffen C Pauws,<sup>1,5</sup> Arjan B te Pas<sup>1</sup>

<sup>1</sup>Willem-Alexander Children's Hospital, Department of Paediatrics, Division of Neonatology, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands  
<sup>2</sup>School of Engineering and ICT, University of Tasmania, Hobart, Tasmania, Australia  
<sup>3</sup>Department of Pediatrics, Royal Hobart Hospital, Hobart, Tasmania, Australia  
<sup>4</sup>Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia  
<sup>5</sup>Tilburg Center for Cognition and Communication, Tilburg University, Tilburg, Noord-Brabant, The Netherlands

## Correspondence to

Dr Hylke H Salverda, Neonatology, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands; H.H.Salverda@lumc.nl

Received 18 January 2021  
Accepted 19 April 2021  
Published Online First 10 June 2021

## ABSTRACT

**Objective** To compare the effect of two different automated oxygen control devices on target range (TR) time and occurrence of hypoxaemic and hyperoxaemic episodes.

**Design** Randomised cross-over study.

**Setting** Tertiary level neonatal unit in the Netherlands.

**Patients** Preterm infants (n=15) born between 24+0 and 29+6 days of gestation, receiving invasive or non-invasive respiratory support with oxygen saturation (SpO<sub>2</sub>) TR of 91%–95%. Median gestational age 26 weeks and 4 days (IQR 25 weeks 3 days–27 weeks 6 days) and postnatal age 19 (IQR 17–24) days.

**Interventions** Inspired oxygen concentration was titrated by the OxyGenie controller (SLE6000 ventilator) and the CLiO<sub>2</sub> controller (AVEA ventilator) for 24 hours each, in a random sequence, with the respiratory support mode kept constant.

**Main outcome measures** Time spent within set SpO<sub>2</sub> TR (91%–95% with supplemental oxygen and 91%–100% without supplemental oxygen).

**Results** Time spent within the SpO<sub>2</sub> TR was higher during OxyGenie control (80.2 (72.6–82.4)% vs 68.5 (56.7–79.3)%, p<0.005). Less time was spent above TR while in supplemental oxygen (6.3 (5.1–9.9)% vs 15.9 (11.5–30.7)%, p<0.005) but more time spent below TR during OxyGenie control (14.7 (11.8%–17.2%) vs 9.3 (8.2–12.6)%, p<0.05). There was no significant difference in time with SpO<sub>2</sub> <80% (0.5 (0.1–1.0)% vs 0.2 (0.1–0.4)%, p=0.061). Long-lasting SpO<sub>2</sub> deviations occurred less frequently during OxyGenie control.

**Conclusions** The OxyGenie control algorithm was more effective in keeping the oxygen saturation within TR and preventing hyperoxaemia and equally effective in preventing hypoxaemia (SpO<sub>2</sub> <80%), although at the cost of a small increase in mild hypoxaemia.

**Trial registry number** NCT03877198

## INTRODUCTION

Oxygen therapy for preterm infants with respiratory insufficiency aims to prevent or moderate the effects of hypoxaemia on the central nervous system, lungs and other organs. Conversely, the immaturity of the premature infant's lungs, eyes and antioxidant system renders them vulnerable to exposure to supplemental oxygen, and hyperoxaemia has been linked to the development of bronchopulmonary dysplasia (BPD) and retinopathy of prematurity (ROP).<sup>1,2</sup>

## What is already known on this topic?

- ▶ Automated oxygen controllers, including the ones used in this study, increase time spent within the oxygen saturation target range compared with manual control.
- ▶ Hypoxaemia and hyperoxaemia have been linked to morbidity and mortality in preterm infants.

## What this study adds?

- ▶ The OxyGenie controller was more effective in keeping the oxygen saturation within SpO<sub>2</sub> target range than the CLiO<sub>2</sub> controller.
- ▶ With OxyGenie, less time was spent above target range, fewer hypoxaemic and hyperoxaemic episodes occurred, although with a small increase in time below target range.
- ▶ Algorithm design influences how effective SpO<sub>2</sub> targeting will be.

Mindful of these morbidities, the inhaled fraction of oxygen (FiO<sub>2</sub>) is titrated manually, based on oxygen saturation (SpO<sub>2</sub>) readings derived from transcutaneous oximetry. Current guidelines recommend a lower limit for the SpO<sub>2</sub> target range (TR) of at least 90% for the preterm infant,<sup>3</sup> based on the recent NeOProM meta-analysis of individual patient data from large randomised controlled trials.<sup>4</sup> These trials highlighted the potential impact of hypoxaemia and hyperoxaemia on preterm infants, with the lower TR (85%–89%) associated with an increased risk of mortality and necrotising enterocolitis and the higher TR (91%–95%) with an increased rate of ROP.

While the need to target an SpO<sub>2</sub> range is widely accepted, data from cohort studies and randomised controlled trials point to the difficulty of SpO<sub>2</sub> targeting by manual oxygen titration,<sup>5–10</sup> with most studies reporting SpO<sub>2</sub> values to be within the TR less than 50% of the time. Although bedside staff adjust the fraction of inspired oxygen (FiO<sub>2</sub>) relatively frequently to maintain SpO<sub>2</sub> within TR, their workload limits time availability and makes it difficult to tailor FiO<sub>2</sub> continuously to the infant's need. This is compounded by the neonatal oxygenation physiology being unstable and non-linear with



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

**To cite:** Salverda HH, Cramer SJE, Witlox RSGM, et al. *Arch Dis Child Fetal Neonatal Ed* 2022;**107**:F20–F25.

significant time delay between  $\text{FiO}_2$  adjustment and when  $\text{SpO}_2$  reaches a new stable level.<sup>11</sup>

Given both the importance and difficulty of  $\text{SpO}_2$  targeting, automated oxygen control (AOC) is a logical improvement on current practice. In essence, the concept is of an  $\text{SpO}_2$  input to a device holding a set of computational instructions (an algorithm), which then gives an output, an updated value for  $\text{FiO}_2$ . Studies comparing automated oxygen titration systems with manual titration, conducted over short periods (2–24 hours per epoch), have demonstrated an absolute increase in the proportion of time spent with  $\text{SpO}_2$  within TR varying between 8% and 31%.<sup>12–23</sup> A single study conducted in our institution has examined the effect of implementation of AOC as standard of care, finding a 14% increase in TR time in the postimplementation cohort, mostly related to a decrease in time above TR.<sup>24</sup>

Although several devices offering AOC are now commercially available and used in neonatal intensive care units (NICUs), comparisons between them are lacking. The NICU of the Leiden University Medical Center (LUMC) implemented AOC with the CLiO<sub>2</sub> algorithm (Vyaire, Yorba Linda, California, USA) with the AVEA ventilator as routine care in August 2015. We recently replaced the AVEA ventilators with SLE6000 ventilators (SLE Limited, South Croydon, UK), which have the VDL 1.1 algorithm for AOC embedded as the “OxyGenie” option.<sup>17 25</sup> This provided the unique setting where caregivers were competent to work with both ventilators, thus making feasible a safe comparison between the two oxygen controllers.

Based on described differences in the function of algorithms developed for AOC, it is likely that they will exhibit differences in performance.<sup>17 25</sup> We recently observed that the CLiO<sub>2</sub> algorithm was effective mostly in decreasing time above TR,<sup>24</sup> whereas the first clinical study using OxyGenie reported a decrease in both time under and above TR and a virtual elimination of longer episodes outside the TR.<sup>23</sup> We therefore hypothesised that the OxyGenie may be more effective than CLiO<sub>2</sub> in maintaining  $\text{SpO}_2$  within the desired TR in preterm infants receiving respiratory support.

## METHODS

### Study setting

We performed a randomised crossover trial in the NICU of the LUMC, a tertiary level neonatal unit with 25 NICU beds and 850 intensive care admissions per year. The Dutch Central Committee on Research Involving Human Subjects approved the study. Written informed parental consent was acquired prior to participation of each infant in the study.

### Study population

Preterm infants born between from 24 weeks and up to and including 29 weeks of gestation who were receiving invasive mechanical ventilation or non-invasive respiratory support were assessed for eligibility. Initially, infants were considered eligible if they required supplemental oxygen with an  $\text{FiO}_2 \geq 0.25$  at the time of enrolment and for at least 18 hours of the preceding 24 hours, but as the study progressed an alternative  $\text{FiO}_2$  eligibility criterion was added ( $\text{FiO}_2$  coefficient of variation  $\geq 0.1$  in the preceding 24 hours) to improve recruitment rate. Infants were excluded in case of major congenital anomalies or acute instability.

### Automated oxygen control algorithms

The CLiO<sub>2</sub> algorithm embedded in the AVEA ventilator is a hybrid rule-based adaptive controller. It makes initial  $\text{FiO}_2$

adjustments that are proportional to the difference between the measured  $\text{SpO}_2$  and the limits of the  $\text{SpO}_2$  TR. Subsequent adjustments also take into account this difference, as well as the  $\text{SpO}_2$  trend and basal oxygen requirement, the *baseFiO<sub>2</sub>*. The *baseFiO<sub>2</sub>* is periodically updated by interrogation of 5 min of recent  $\text{SpO}_2$  and  $\text{FiO}_2$  data where specific conditions are met, averaged along with the current *baseFiO<sub>2</sub>* value.<sup>26</sup>

The OxyGenie algorithm embedded in the SLE6000 ventilator is an adaptive proportional-integral-derivative (PID) controller. The P, I and D terms each have separate coefficients, and in each case are adjusted from raw values to better suit the physiology of a neonate and account for the limitations of pulse oximetry. The basal  $\text{FiO}_2$ , referred to as *Reference FiO<sub>2</sub>*, is calculated every 30 min using 60 min of preceding  $\text{FiO}_2$  and  $\text{SpO}_2$  values.

### Study procedures

A crossover design was used to study each infant on the same respiratory support mode. Infants received two consecutive study periods of 24 hours each, one with oxygen therapy under the control of the CLiO<sub>2</sub> algorithm and the other with the OxyGenie algorithm, in random sequence. Web-based randomisation by Castor EDC (Castor, Amsterdam, The Netherlands) was used, stratified by mode of respiratory support (invasive or non-invasive) using variable (4, 6) block sizes. After the first study period, the alternative ventilator was substituted, and a washout period of 1 hour was applied before data recording restarted to prevent a carryover bias. The study was completed when AOC with each device had been applied for 24 hours, with standard respiratory management thereafter resuming. The  $\text{SpO}_2$  TR for both study periods was 91%–95%.

No other extra interventions were given. Infants did receive all standard treatments, and ventilation settings were at the discretion of the caregiver.

### Data collection and analysis

Baseline characteristics were noted for each infant, including details on respiratory support and clinical state. The primary outcome was the proportion of time spent within the  $\text{SpO}_2$  TR (91%–95% with supplemental oxygen or 91%–100% without supplemental oxygen).  $\text{SpO}_2$  and intended  $\text{FiO}_2$  values were recorded each second from the data port or display of the ventilator under investigation. Secondary outcomes included: proportion of time in various degrees of hypoxaemia ( $\text{SpO}_2 < 80\%$ ,  $\text{SpO}_2 80\%$ – $84\%$ ,  $\text{SpO}_2 85\%$ – $90\%$ ,  $\text{SpO}_2 \leq 90\%$ ) and hyperoxaemia ( $\text{SpO}_2 > 95\%$ ,  $\text{SpO}_2 96\%$ – $98\%$  and  $\text{SpO}_2 > 98\%$  while receiving supplemental oxygen);  $\text{SpO}_2$  and  $\text{FiO}_2$  coefficient of variation; frequency of 30 and 60s episodes in hypoxaemia and hyperoxaemia; bradycardic episodes (heart rate  $< 100$  beats per minute for  $\geq 10$  consecutive seconds); frequency of  $\text{FiO}_2$  adjustments, both manual and automatic and average oxygen exposure.

Continuous data are represented as median (IQR) or mean  $\pm$  SD as appropriate, with standard tests for normality. Time within particular  $\text{SpO}_2$  ranges was collated for each infant individually and expressed as proportion of usable recorded time. Differences in time in TR and other outcomes were assessed with the Wilcoxon matched-pairs test. The intention-to-treat principle was applied. Statistical analyses were performed by an analyst blinded to allocation using R V.3.4.4 (R Core Team (2016). R: A language and environment for statistical computing, R Foundation for Statistical Computing, Vienna, Austria, URL: <https://www.R-project.org/>).




Figure 1 CONSORT flow diagram.

Sample size calculation was based around data from previous studies of the two automated control algorithms. In a study using the CLiO<sub>2</sub> in Leiden in preterm infants the proportion of time in the SpO<sub>2</sub> TR was 60.4% (±15.6%).<sup>24</sup> In the first clinical study of the OxyGenie algorithm TR time was 78% (±15%). We considered a difference of 5% TR time a clinically relevant difference. For a two-sided paired statistical test, 44 infants would be needed assuming a SD of 10% for a power of 90% and an alpha of 0.05. Because a non-parametric test would be




Figure 2 SpO<sub>2</sub> histograms. Pooled time spent per SpO<sub>2</sub> value as proportion of total usable time, while receiving supplemental oxygen and ambient air (total) or while only receiving supplemental oxygen. Dashed lines represent the limits of the SpO<sub>2</sub> target range.

Table 1 Baseline characteristics

Characteristic	Definition	Statistics	Results
Gestational age	weeks, days	Median (IQR)	26.4 (25.3–27.6)
Birth weight	g	Median (IQR)	945 (740–1120)
Postnatal age	days	Median (IQR)	19 (17–24)
Gender	Female/male	n	4/11
Ventilation mode	Invasive ventilation/CPAP	n	2/13
Average FiO <sub>2</sub> over 24 hours prestudy	Fraction	Median (IQR)	0.26 (0.24–0.29)
Weight at study entry	g	Median (IQR)	1197 (1021–1300)
Allocation	OxyGenie first/CLiO <sub>2</sub> first	n	7/8

CPAP, continuous positive airway pressure; FiO<sub>2</sub>, fraction of inspired oxygen.

used in the analysis, we made a 15% addition to the sample size, as described by Lehmann,<sup>27</sup> requiring a total of 50 participants.

### Early termination

Just prior to study commencement, the SLE6000 ventilator was deployed as the standard device for neonatal respiratory support at LUMC. The AVEA ventilators were thereafter only used when an infant was included in the study. Based on historical data, we anticipated to complete recruitment in a year, which was also considered the maximum time competence of medical staff in working with both ventilators could be guaranteed. However, the recruitment rate was slower than expected and to ensure patient safety and an unbiased comparison of both oxygen control with the two ventilators the trial was terminated after a 12-month recruiting period.

### RESULTS

The study ran from February 2019 to February 2020, during which consent was sought from 27 parent couples of which 15 agreed to participate (figure 1). All participating infants (n=15, baseline characteristics table 1) completed the crossover comparison. In one infant, the second study period (OxyGenie control) was halted after 18 hours to allow treating clinicians to switch from continuous positive airway pressure to nasal high flow in response to nasal pressure areas. All study periods were included in the analysis. The total duration of recordings was 23 hours and 19 min (22:52–23:30) during OxyGenie control and 23 hours and 51 min (23:49–23:56) with the CLiO<sub>2</sub> controller. A total of 2.9% (2.1%–5.0%) and 0.3% (0.2%–0.6%) of the time the SpO<sub>2</sub> signal was missing, respectively.


Histograms of pooled SpO<sub>2</sub> data from the two automated control periods are shown in figure 2, demonstrating a narrower SpO<sub>2</sub> distribution and a lower median SpO<sub>2</sub> during OxyGenie control resulting in a higher proportion of time within the SpO<sub>2</sub> TR. On per patient analysis, for the study primary outcome, there was a 11.7% increase in time within the SpO<sub>2</sub> TR during oxygen control with the OxyGenie algorithm when compared with the CLiO<sub>2</sub> device (table 2). Twelve infants spent more time in TR with OxyGenie control and three with CLiO<sub>2</sub> control (figure 3). During the OxyGenie period, less time was spent above the TR while in supplemental oxygen, but more time spent below TR. SpO<sub>2</sub> values <80% were very infrequent throughout the study, and the time with SpO<sub>2</sub> <80% did not differ between control devices. The coefficient of variation for SpO<sub>2</sub> was similar for both devices (3.3% (2.6%–4.0%) vs 3.2% (3.0%–3.4%), p=0.82).

**Table 2** Proportions of time within SpO<sub>2</sub> ranges

	Oxygenie	CLiO <sub>2</sub>	P value*
Time SpO <sub>2</sub> within target range†	80.2 (72.6–82.4)%	68.5 (56.7–79.3)%	0.005
Time SpO <sub>2</sub> below target range	14.7 (11.8–17.2)%	9.3 (8.2–12.6)%	0.020
Time SpO <sub>2</sub> above target range‡	6.3 (5.1–9.9)%	15.9 (11.5–30.7)%	0.001
SpO <sub>2</sub> 85%–90%	12.6 (10.9–13.1)%	8.5 (7.6–11.0)%	0.020
SpO <sub>2</sub> 80%–84%	1.2 (0.7–3.0)%	0.8 (0.5–0.9)%	0.003
SpO <sub>2</sub> <80%	0.5 (0.1–1.0)%	0.2 (0.1–0.4)%	0.061
SpO <sub>2</sub> 96%–98% while FiO <sub>2</sub> ≥0.22	6.1 (5.0–9.5)%	15.5 (10.9–27.4)%	0.001
SpO <sub>2</sub> >98% while FiO <sub>2</sub> ≥0.22	0.2 (0.1–0.4)%	1.4 (0.4–3.7)%	0.001

Data in median (IQR)

\*Wilcoxon matched pairs test.

†91% ≤SpO<sub>2</sub> ≤95% or SpO<sub>2</sub> ≥96% while FiO<sub>2</sub>=0.21.‡SpO<sub>2</sub> ≥96% while FiO<sub>2</sub> ≥0.22.

**Figure 3** Comparison of OxyGenie control with CLiO<sub>2</sub> control. Individual paired values of proportion of time within TR while on OxyGenie control and while on CLiO<sub>2</sub> control. Horizontal bar=median. Within TR=91%–95% with supplemental oxygen or 91%–100% without supplemental oxygen. TR, target range.

There was a decrease in frequency of both hypoxaemic and hyperoxaemic episodes during OxyGenie control (table 3). Bradycardic episodes (<100bpm for ≥10s) were rare in both epochs and were not different (0.3 (0.1–0.6) vs 0.2 (0.0–0.5) per hour, p=0.22).

OxyGenie adjusted FiO<sub>2</sub> about 10 times more frequently than the CLiO<sub>2</sub> device (1155 (1044–1255) vs 194 (178–205) adjustments/hour, p=0.001). The average delivered FiO<sub>2</sub> was similar during both study periods (0.27+–0.05 vs 0.26 +–0.08, p=0.56). FiO<sub>2</sub> was more variable when titrated by the OxyGenie algorithm (coefficient of variation 19.5% (15.2%–25.0%) vs 13.3% (12.8%–19.0%), p=0.015). During OxyGenie control, manual overrides of the AOC were made only in one individual subject (four adjustments) versus nine individuals (16 adjustments) with manual overrides during the period of CLiO<sub>2</sub> oxygen control.

## DISCUSSION

In this randomised controlled crossover study, automated titration of inspired oxygen concentration using the OxyGenie controller significantly increased the time spent within the SpO<sub>2</sub> TR when compared with the CLiO<sub>2</sub> controller. The difference in controller function was reflected in the SpO<sub>2</sub> histogram, with a more balanced distribution of SpO<sub>2</sub> values within and around the TR during OxyGenie control. This resulted in significantly less time spent above the TR, and fewer hyperoxaemic episodes, although at the cost of a small increase in time spent with SpO<sub>2</sub> values below TR. The greater time with SpO<sub>2</sub> in the range 80%–90% with OxyGenie compared with CLiO<sub>2</sub> control was not accompanied by an increase in the frequency of hypoxic episodes, which were, indeed, significantly fewer during OxyGenie control. These results suggest that algorithm design, and in particular algorithm responsiveness, plays an important role in how successful SpO<sub>2</sub> targeting will be with a given oxygen control device.

This is the first study to compare two different ventilators incorporating AOC algorithms head-to-head. Although earlier studies have individually compared the algorithms in question to manual oxygen titration,<sup>15–20 23 24</sup> heterogeneity between the studies has precluded drawing inferences about their function relative to each other. Our findings in relation to proportion of time within TR were similar to previous studies, implying that the SpO<sub>2</sub> targeting results achieved by controllers in our study were representative of their overall performance. Compared with the TR time of 80% in this study, other studies of OxyGenie control have demonstrated TR times of 81%<sup>23</sup> and 88%.<sup>28</sup> For CLiO<sub>2</sub> (69% TR time in this study), other studies have shown TR time of 40%,<sup>15</sup> 58%,<sup>16</sup> 62%,<sup>18</sup> 76%,<sup>19</sup> 73%<sup>20</sup> and 62%<sup>24</sup>.

The study was terminated before reaching the predetermined sample size of 50 infants. The deployment of the SLE6000 ventilator at LUMC had an impact on numbers of eligible infants by virtue of (1) the option of nasal high flow (not available with the AVEA ventilator) being taken up at an early juncture in many preterm infants, precluding involvement in the study and (2) fewer infants spending >18 of the preceding 24 hours with an FiO<sub>2</sub> ≥0.25, in part attributable to the progressive approach to weaning FiO<sub>2</sub> inherent in OxyGenie control. As a result, the recruitment rate was lower than expected. To prevent a loss of competence in handling the AVEA ventilator, potentially introducing a bias into the study, we decided to terminate the study prematurely. Truncated clinical studies can lead to overexaggerated observed effects.<sup>29 30</sup> For our study, this would mean that the observed benefit for the OxyGenie controller in comparison



**Table 3** Hypoxaemic and hyperoxaemic episodes

	30 s episodes/6 hours			60 s episodes/6 hours		
	Oxygenie	CLiO <sub>2</sub>	P value*	Oxygenie	CLiO <sub>2</sub>	P value*
SpO <sub>2</sub> <85%	0.5 (0.2–1.1)	0.8 (0.5–1.7)	0.022	0 (0–0.24)	0.2 (0–0.8)	0.027
SpO <sub>2</sub> <80%	0 (0–0)	0.2 (0–0.5)	0.011	0 (0–0)	0 (0–0)	0.257
SpO <sub>2</sub> >95%†	4.4 (2.6–10.7)	37.3 (15.8–54.3)	0.009	0.8 (0.4–2.6)	14.6 (5.5–22.8)	0.008
SpO <sub>2</sub> >98%†	0.2 (0–0.8)	6.3 (1.7–13.6)	0.004	0 (0–0.2)	1.7 (0.5–5.3)	0.002

Data in median (IQR).

\*Wilcoxon matched pairs test.

†While FiO<sub>2</sub> ≥ 0.22.

to CLiO<sub>2</sub> controller may overestimate the true benefit. However, if we had planned for an interim analysis to decide for stopping the trial after 15 patients, we would have surpassed both the Pocock and O'Brien-Fleming boundary criteria for clearly showing evidence of benefit for the OxyGenie controller. For a single interim analysis, Pocock recommends a p-threshold of 0.0294<sup>31</sup> and O'Brien-Fleming recommends a more conservative 0.0054 p-threshold<sup>32</sup> to control for type I error due to repeated testing. The apparent benefit of OxyGenie is also demonstrated by a 11.7% improvement which is more than twice the clinically relevant difference of 5% for which the current study was powered.

There was an imbalance between the two oxygen control devices in the proportion of missing values. Both algorithms use a built-in Masimo pulse oximeter with similar algorithms making it unlikely that the actual reliability of pulse oximeter measurement was different between ventilators. But, to ensure a prompt response to TR deviations, OxyGenie uses a 2–4 s averaging time whereas CLiO<sub>2</sub> uses an 8 s averaging time. This could lead to more missing signal, as shorter averaging times are inherently more susceptible to disturbances. Furthermore, although the same SET technology is used, manufacturers are free to choose the signal quality threshold below which SpO<sub>2</sub> is reported as missing. It seems likely that the handling of the SpO<sub>2</sub> signal within the SLE6000 is more conservative in this respect. Because the proportion of missing signal was still relatively low in both oxygen control periods, its effect on the outcomes of this study is likely to have been modest.

This study compared two ventilators rather than purely the AOC algorithms. It is possible that ventilator mechanics also played a role in the effectiveness of oxygen control as well as other aspects of ventilator function including the circuit flow characteristics.<sup>33</sup> However, this was a pragmatic choice as license agreements precluded us from implementing two algorithms in one ventilator.

Contrary to our hypothesis, the benefit of an increase in SpO<sub>2</sub> TR time with OxyGenie control was gained with a lesser occurrence of hyperoxaemia, at the cost of a minor increase in time spent with SpO<sub>2</sub> 80%–90%. Although at first glance it appears there is a trade-off between hyperoxaemia and hypoxaemia, the reduction in hypoxaemic episodes with OxyGenie control suggests that hypoxaemia is resolved more quickly. This is in line with the clinical observation of caregivers, who reported that OxyGenie responded more rapidly to SpO<sub>2</sub> deviations into hypoxaemia than CLiO<sub>2</sub>. Compared with other studies, time with SpO<sub>2</sub> <80% was modest with both controllers. For the OxyGenie controller, it was 0.5% in our study vs 0%<sup>23</sup> previously; for the CLiO<sub>2</sub> controller, it was 0.2% whereas other studies reported 9.8%,<sup>15</sup> 1.2% and 0.8%,<sup>18</sup> 3.1%,<sup>19</sup> 1.3%<sup>20</sup> and 0.9%.<sup>24</sup>

The increase in time spent under TR could be due to a lower median SpO<sub>2</sub> during OxyGenie control (93% vs 94%) on the steeper part of the oxygen-dissociation curve. The higher median SpO<sub>2</sub> during CLiO<sub>2</sub> control could be because, according to the patent, an SpO<sub>2</sub> of 94% is targeted while in TR and the FiO<sub>2</sub> is rarely titrated below the *BaseFiO<sub>2</sub>*.<sup>26</sup>

Even though the benefit of AOC on SpO<sub>2</sub> TR time is well-established, the effect on clinical outcome is still unknown. The effect of SpO<sub>2</sub> targeting within different ranges on clinical outcome was demonstrated by the NeOPRoM trials,<sup>4</sup> and a range of studies have evidenced the harmful effects of hypoxaemia and hyperoxaemia (and episodes thereof),<sup>34–39</sup> both of which are affected by AOC. We would maintain that when searching for clinical effect of AOC, it is important to use an algorithm that most successfully avoids and mitigates SpO<sub>2</sub> deviations, because the effect on clinical outcomes may be modest and in some cases may be difficult to detect given their relatively low incidence.

Finally, low compliance in TR adherence such as reported in the NeOPRoM trials<sup>4</sup> could be improved on by using AOC. For the best differentiation between treatment groups, it is important to have a controller that best targets the predefined ranges.

## CONCLUSION

In this study, the OxyGenie controller was more effective in keeping the oxygen saturation within TR and preventing hyperoxaemia, and just as effective in preventing hypoxaemia (SpO<sub>2</sub> <80%), although at the cost of a small increase with SpO<sub>2</sub> 80%–90%.

**Twitter** Arjan B te Pas @None

**Contributors** HHS: co-conceived the study (with ABtP) conducted the study, compiled, analysed and interpreted the data (with SCP), co-wrote the first draft of the manuscript and approved the final version of the manuscript. SJEC: reviewed and edited the manuscript, conducted the study and approved the final version of the manuscript. RSGMW: reviewed and edited the manuscript, acquired data and approved the final version of the manuscript. TJG: reviewed and edited the manuscript, interpreted the data and approved the final version of the manuscript. PAD: interpreted the data, reviewed and edited the manuscript and approved the final version of the manuscript. SCP: reviewed and edited the manuscript, performed the analysis and interpretation of the data and approved the final version of the manuscript. ABtP: co-conceived the study, oversaw the study conduct, interpreted the data, cowrote the first draft of the manuscript and approved the final version.

**Funding** This work was supported by SLE Limited by an unrestricted research grant.

**Disclaimer** SLE Limited had no role in study design nor in the collection, analysis and interpretation of data, writing of the report and decision to submit the paper for publication.

**Competing interests** ABtP has received an unrestricted research grant from SLE Limited; they had no role in study design nor in the collection, analysis, and interpretation of data, writing of the report and decision to submit the paper for publication. The University of Tasmania and Royal Hobart Hospital have a patent concerning automated control of inspired oxygen concentration in the new-born infant and have a licensing agreement with SLE Limited in relation to OxyGenie automated oxygen control software.

**Patient consent for publication** Not required.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available on reasonable request.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

#### ORCID iD

Hylke H Salverda <http://orcid.org/0000-0001-9355-5993>

## REFERENCES

- Higgins RD, Jobe AH, Koso-Thomas M, *et al.* Bronchopulmonary dysplasia: Executive summary of a workshop. *J Pediatr* 2018;197:300–8.
- Hellström A, Hård A-L. Screening and novel therapies for retinopathy of prematurity - A review. *Early Hum Dev* 2019;138:104846.
- Sweet DG, Carnielli V, Greisen G, *et al.* European Consensus Guidelines on the Management of Respiratory Distress Syndrome - 2019 Update. *Neonatology* 2019;115:432–50.
- Askie LM, Darlow BA, Finer N, *et al.* Association between oxygen saturation targeting and death or disability in extremely preterm infants in the neonatal oxygenation prospective meta-analysis collaboration. *JAMA* 2018;319:2190–201.
- Hagadorn JI, Furey AM, Nghiem T-H, *et al.* Achieved versus intended pulse oximeter saturation in infants born less than 28 weeks' gestation: the AVIOx study. *Pediatrics* 2006;118:1574–82.
- SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network, Carlo WA, Finer NN, *et al.* Target ranges of oxygen saturation in extremely preterm infants. *N Engl J Med* 2010;362:1959–69.
- Lim K, Wheeler KI, Gale TJ, *et al.* Oxygen saturation targeting in preterm infants receiving continuous positive airway pressure. *J Pediatr* 2014;164:730–6.
- Schmidt B, Whyte RK, Asztalos EV, *et al.* Effects of targeting higher vs lower arterial oxygen saturations on death or disability in extremely preterm infants: a randomized clinical trial. *JAMA* 2013;309:2111–20.
- BOOST II United Kingdom Collaborative Group, BOOST II Australia Collaborative Group, BOOST II New Zealand Collaborative Group, *et al.* Oxygen saturation and outcomes in preterm infants. *N Engl J Med* 2013;368:2094–104.
- Clarke A, Yeomans E, Elsayed K, *et al.* A randomised crossover trial of clinical algorithm for oxygen saturation targeting in preterm infants with frequent desaturation episodes. *Neonatology* 2015;107:130–6.
- Sadeghi Fathabadi O, Gale TJ, Lim K, *et al.* Characterisation of the oxygenation response to inspired oxygen adjustments in preterm infants. *Neonatology* 2016;109:37–43.
- Urschitz MS, Horn W, Seyfang A, *et al.* Automatic control of the inspired oxygen fraction in preterm infants: a randomized crossover trial. *Am J Respir Crit Care Med* 2004;170:1095–100.
- Hallenberger A, Poets CF, Horn W, *et al.* Closed-Loop automatic oxygen control (CLAC) in preterm infants: a randomized controlled trial. *Pediatrics* 2014;133:e379–85.
- Schwarz CE, Kidszun A, Bieder NS, *et al.* Is faster better? a randomised crossover study comparing algorithms for closed-loop automatic oxygen control. *Arch Dis Child Fetal Neonatal Ed* 2020;105:369–74.
- Claire N, Bancalari E, D'Ugard C, *et al.* Multicenter crossover study of automated control of inspired oxygen in ventilated preterm infants. *Pediatrics* 2011;127:e76–83.
- Claire N, D'Ugard C, Bancalari E. Automated adjustment of inspired oxygen in preterm infants with frequent fluctuations in oxygenation: a pilot clinical trial. *J Pediatr* 2009;155:640–5.
- Claire N, Gerhardt T, Everett R, *et al.* Closed-Loop controlled inspired oxygen concentration for mechanically ventilated very low birth weight infants with frequent episodes of hypoxemia. *Pediatrics* 2001;107:1120–4.
- van Kaam AH, Hummler HD, Wilinska M, *et al.* Automated versus manual oxygen control with different saturation targets and modes of respiratory support in preterm infants. *J Pediatr* 2015;167:545–50.
- Waitz M, Schmid MB, Fuchs H, *et al.* Effects of automated adjustment of the inspired oxygen on fluctuations of arterial and regional cerebral tissue oxygenation in preterm infants with frequent desaturations. *J Pediatr* 2015;166:240–4.
- Lal M, Tin W, Sinha S. Automated control of inspired oxygen in ventilated preterm infants: crossover physiological study. *Acta Paediatr* 2015;104:1084–9.
- Gajdos M, Waitz M, Mendler MR, *et al.* Effects of a new device for automated closed loop control of inspired oxygen concentration on fluctuations of arterial and different regional organ tissue oxygen saturations in preterm infants. *Arch Dis Child Fetal Neonatal Ed* 2019;104:F360–5.
- Reynolds PR, Miller TL, Volakis LI, *et al.* Randomised cross-over study of automated oxygen control for preterm infants receiving nasal high flow. *Arch Dis Child Fetal Neonatal Ed* 2019;104:F366–71.
- Plottier GK, Wheeler KI, Ali SKM, *et al.* Clinical evaluation of a novel adaptive algorithm for automated control of oxygen therapy in preterm infants on non-invasive respiratory support. *Arch Dis Child Fetal Neonatal Ed* 2017;102:F37–43.
- Van Zanten HA, Kuypers KLAM, Stenson BJ, *et al.* The effect of implementing an automated oxygen control on oxygen saturation in preterm infants. *Arch Dis Child Fetal Neonatal Ed* 2017;102:F395–9.
- Dargaville PA, Sadeghi Fathabadi O, Plottier GK, *et al.* Development and preclinical testing of an adaptive algorithm for automated control of inspired oxygen in the preterm infant. *Arch Dis Child Fetal Neonatal Ed* 2017;102:F31–6.
- Claire NR, Bancalari EH. *System and method for closed loop controlled inspired oxygen concentration*. Google Patents, 2003.
- Lehmann. *Nonparametrics: statistical methods based on ranks*. New York: Springer, 2006.
- Sturrock S, Ambulker H, Williams EE, *et al.* A randomised crossover trial of closed loop automated oxygen control in preterm. *ventilated infants.n/a(n/a)*.
- Pocock SJ, Hughes MD. Practical problems in interim analyses, with particular regard to estimation. *Control Clin Trials* 1989;10:209–21.
- Briel M, Lane M, Montori VM, *et al.* Stopping randomized trials early for benefit: a protocol of the study of trial policy of interim Truncation-2 (STOPIT-2). *Trials* 2009;10:49.
- POCOCK SJ. Group sequential methods in the design and analysis of clinical trials. *Biometrika* 1977;64:191–9.
- O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. *Biometrics* 1979;35:549–56.
- Schwarz CE, Lightbody G, Müller-Hansen I, *et al.* In vitro evaluation of delays in the adjustment of the fraction of inspired oxygen during CPAP: effect of flow and volume. *Arch Dis Child Fetal Neonatal Ed* 2021;106:F205–7.
- Poets CF, Roberts RS, Schmidt B, *et al.* Association between intermittent hypoxemia or bradycardia and late death or disability in extremely preterm infants. *JAMA* 2015;314:595–603.
- Hellstrom A, Perruzzi C, Ju M, *et al.* Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. *Proc Natl Acad Sci U S A* 2001;98:5804–8.
- Haynes RL, Folkerth RD, Keefe RJ, *et al.* Nitrosative and oxidative injury to premyelinating oligodendrocytes in periventricular leukomalacia. *J Neuropathol Exp Neurol* 2003;62:441–50.
- Askie LM, Darlow BA, Davis PG, *et al.* Effects of targeting lower versus higher arterial oxygen saturations on death or disability in preterm infants. *Cochrane Database Syst Rev* 2017;4:Cd011190.
- Martin RJ, Wang K, Köroğlu O, *et al.* Intermittent hypoxic episodes in preterm infants: do they matter? *Neonatology* 2011;100:303–10.
- Di Fiore JM, Bloom JN, Orge F, *et al.* A higher incidence of intermittent hypoxic episodes is associated with severe retinopathy of prematurity. *J Pediatr* 2010;157:69–73.